Recursion Stock Based Compensation vs Begin Period Cash Flow Analysis

RXRX Stock  USD 6.53  0.13  2.03%   
Recursion Pharmaceuticals financial indicator trend analysis is much more than just breaking down Recursion Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Recursion Pharmaceuticals is a good investment. Please check the relationship between Recursion Pharmaceuticals Stock Based Compensation and its Begin Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.

Stock Based Compensation vs Begin Period Cash Flow

Stock Based Compensation vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Recursion Pharmaceuticals Stock Based Compensation account and Begin Period Cash Flow. At this time, the significance of the direction appears to have totally related.
The correlation between Recursion Pharmaceuticals' Stock Based Compensation and Begin Period Cash Flow is 0.99. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Recursion Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Recursion Pharmaceuticals' Stock Based Compensation and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Recursion Pharmaceuticals are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Stock Based Compensation i.e., Recursion Pharmaceuticals' Stock Based Compensation and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.99
Relationship DirectionPositive 
Relationship StrengthVery Strong

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most indicators from Recursion Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Recursion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.Issuance Of Capital Stock is likely to rise to about 255.1 M in 2025, whereas Selling General Administrative is likely to drop slightly above 64.7 M in 2025.
 2022 2023 2024 2025 (projected)
Depreciation And Amortization11.8M24.4M28.1M29.5M
Interest Income6.3M18.3M21.0M22.1M

Recursion Pharmaceuticals fundamental ratios Correlations

0.820.950.970.950.880.940.95-0.94-0.920.960.970.850.970.47-0.970.980.780.76-0.580.87-0.90.810.92-0.290.94
0.820.820.940.740.910.750.95-0.78-0.890.920.850.850.740.09-0.760.70.330.86-0.480.91-0.830.820.81-0.190.74
0.950.820.930.880.860.880.93-0.83-0.930.90.890.880.90.23-0.910.880.710.88-0.520.84-0.930.870.9-0.250.88
0.970.940.930.90.930.90.99-0.92-0.940.990.970.880.910.34-0.930.910.620.82-0.570.93-0.910.840.91-0.260.9
0.950.740.880.90.851.00.9-0.86-0.910.930.870.880.970.47-0.990.930.840.72-0.760.88-0.920.840.98-0.531.0
0.880.910.860.930.850.860.92-0.87-0.960.90.910.960.790.11-0.870.810.470.83-0.440.99-0.940.940.92-0.150.85
0.940.750.880.91.00.860.9-0.86-0.920.930.870.890.970.45-0.990.920.830.74-0.760.89-0.930.850.98-0.531.0
0.950.950.930.990.90.920.9-0.88-0.940.990.930.890.910.31-0.920.870.610.85-0.630.93-0.910.850.92-0.340.9
-0.94-0.78-0.83-0.92-0.86-0.87-0.86-0.880.85-0.9-0.99-0.77-0.88-0.520.91-0.96-0.64-0.590.4-0.840.8-0.71-0.830.09-0.86
-0.92-0.89-0.93-0.94-0.91-0.96-0.92-0.940.85-0.92-0.89-0.97-0.86-0.140.92-0.84-0.6-0.870.56-0.970.99-0.96-0.960.29-0.91
0.960.920.90.990.930.90.930.99-0.9-0.920.940.860.940.41-0.940.90.650.8-0.680.92-0.890.820.93-0.40.93
0.970.850.890.970.870.910.870.93-0.99-0.890.940.820.90.45-0.920.950.630.7-0.430.88-0.840.760.86-0.120.87
0.850.850.880.880.880.960.890.89-0.77-0.970.860.820.790.02-0.870.760.540.89-0.540.97-0.980.990.96-0.310.88
0.970.740.90.910.970.790.970.91-0.88-0.860.940.90.790.59-0.980.960.870.69-0.740.81-0.860.740.92-0.50.97
0.470.090.230.340.470.110.450.31-0.52-0.140.410.450.020.59-0.490.610.68-0.14-0.460.13-0.12-0.070.28-0.370.47
-0.97-0.76-0.91-0.93-0.99-0.87-0.99-0.920.910.92-0.94-0.92-0.87-0.98-0.49-0.96-0.83-0.710.69-0.880.92-0.83-0.960.44-0.99
0.980.70.880.910.930.810.920.87-0.96-0.840.90.950.760.960.61-0.960.830.61-0.540.8-0.820.710.87-0.260.93
0.780.330.710.620.840.470.830.61-0.64-0.60.650.630.540.870.68-0.830.830.42-0.710.49-0.650.50.72-0.580.84
0.760.860.880.820.720.830.740.85-0.59-0.870.80.70.890.69-0.14-0.710.610.42-0.490.83-0.880.910.82-0.270.72
-0.58-0.48-0.52-0.57-0.76-0.44-0.76-0.630.40.56-0.68-0.43-0.54-0.74-0.460.69-0.54-0.71-0.49-0.540.61-0.51-0.710.94-0.76
0.870.910.840.930.880.990.890.93-0.84-0.970.920.880.970.810.13-0.880.80.490.83-0.54-0.940.950.95-0.280.88
-0.9-0.83-0.93-0.91-0.92-0.94-0.93-0.910.80.99-0.89-0.84-0.98-0.86-0.120.92-0.82-0.65-0.880.61-0.94-0.97-0.980.37-0.92
0.810.820.870.840.840.940.850.85-0.71-0.960.820.760.990.74-0.07-0.830.710.50.91-0.510.95-0.970.93-0.280.84
0.920.810.90.910.980.920.980.92-0.83-0.960.930.860.960.920.28-0.960.870.720.82-0.710.95-0.980.93-0.480.98
-0.29-0.19-0.25-0.26-0.53-0.15-0.53-0.340.090.29-0.4-0.12-0.31-0.5-0.370.44-0.26-0.58-0.270.94-0.280.37-0.28-0.48-0.53
0.940.740.880.91.00.851.00.9-0.86-0.910.930.870.880.970.47-0.990.930.840.72-0.760.88-0.920.840.98-0.53
Click cells to compare fundamentals

Recursion Pharmaceuticals Account Relationship Matchups

Recursion Pharmaceuticals fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets298.6M610.3M701.3M653.7M751.8M520.4M
Short Long Term Debt Total15.7M11.5M51.0M50.7M58.3M31.9M
Other Current Liab19.7M32.3M27.0M46.6M53.6M28.7M
Total Current Liabilities23.1M46.7M100.3M93.2M107.1M59.4M
Total Stockholder Equity(206.3M)542.9M485.8M463.4M533.0M559.6M
Property Plant And Equipment Net26.0M64.7M121.4M120.2M138.2M78.5M
Net Debt(246.5M)(273.6M)(498.9M)(340.9M)(306.8M)(322.1M)
Retained Earnings(213.6M)(400.1M)(639.6M)(967.6M)(870.9M)(827.3M)
Accounts Payable1.1M2.8M4.6M4.0M4.5M3.0M
Cash262.1M285.1M549.9M391.6M450.3M342.9M
Non Current Assets Total29.1M75.6M131.5M215.6M247.9M260.3M
Non Currrent Assets Other650K8.7M7.9M6.9M7.9M5.5M
Other Assets650K8.7M7.9M1.01.151.09
Long Term Debt11.4M633K536K1.1M990.9K941.4K
Cash And Short Term Investments262.1M516.6M549.9M391.6M450.3M393.8M
Net Receivables156K9.1M2.8M3.1M3.6M3.4M
Liabilities And Stockholders Equity298.6M610.3M701.3M653.7M751.8M520.4M
Non Current Liabilities Total481.8M20.7M115.2M97.1M87.4M149.4M
Capital Lease Obligations3.2M10.8M50.4M49.5M57.0M59.8M
Inventory5.0M1.6M1.3M(3.1M)(2.8M)(2.6M)
Other Current Assets2.2M9.1M17.1M43.5M50.0M52.5M
Other Stockholder Equity(441M)943.1M1.1B1.4B1.6B1.7B
Total Liab504.9M67.4M215.5M190.3M171.2M192.6M
Net Invested Capital(193.8M)543.7M486.4M464.6M534.3M561.0M
Property Plant And Equipment Gross26.0M83.5M121.4M165.0M189.8M199.3M
Short Long Term Debt1.1M90K97K41K36.9K35.1K
Total Current Assets269.5M534.7M569.8M438.1M503.9M415.5M
Net Working Capital246.4M488.1M469.5M345.0M396.7M356.1M
Short Term Debt2.0M1.5M12.0M6.2M7.1M4.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.